Cancer Letters
Volume 299, Issue 1 , Pages 54-62 , 18 December 2010

Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death

  • Xiaowei Gong

      Affiliations

    • Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden
    • Department of Pathophysiology and Key Laboratory of Proteomics of Guangdong Province, Southern Medical University, Guangzhou 510515, China
    • Contributed equally to this study.
    • ,
  • Zhengwen An

      Affiliations

    • Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden
    • Contributed equally to this study.
    • ,
  • Yunling Wang

      Affiliations

    • Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden
    • ,
  • Lizhao Guan

      Affiliations

    • Key Laboratory of Carcinogenesis and Translational Research, The Ministry of Education, Laboratory of Molecular Cell Biology and Tumor Biology, Department of Histology, Embryology and Pathology, Peking University Health Science Center, Beijing 100191, China
    • ,
  • Weigang Fang

      Affiliations

    • Key Laboratory of Carcinogenesis and Translational Research, The Ministry of Education, Laboratory of Molecular Cell Biology and Tumor Biology, Department of Histology, Embryology and Pathology, Peking University Health Science Center, Beijing 100191, China
    • ,
  • Staffan Strömblad

      Affiliations

    • Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden
    • ,
  • Yong Jiang

      Affiliations

    • Department of Pathophysiology and Key Laboratory of Proteomics of Guangdong Province, Southern Medical University, Guangzhou 510515, China
    • Corresponding Author InformationCorrespondence to: Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China. Tel.: +86 20 61648231.
    • ,
  • Hongquan Zhang

      Affiliations

    • Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden
    • Key Laboratory of Carcinogenesis and Translational Research, The Ministry of Education, Laboratory of Molecular Cell Biology and Tumor Biology, Department of Histology, Embryology and Pathology, Peking University Health Science Center, Beijing 100191, China
    • Corresponding Author InformationCorrespondence to: Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Stockholm, Sweden. Tel.: +46 8 608 9267; fax: +46 8 608 1501.

Received 2 June 2010 ,Revised 5 August 2010 ,Accepted 9 August 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008, CA. Cancer J. Clin. 2008;58:71–96
  2. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA. 2008;105:17356–17361
  3. Orlandi L, Binda M, Folini M, Bearzatto A, Villa R, Daidone MG, et al. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate. 2003;54:133–143
  4. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am. J. Clin. Oncol. 1999;22:471–474
  5. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007;178:844–848(discussion 848)
  6. Lu Y, Zhang X, Beheshti B, Zhang J. Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis. Prostate. 2009;69:234–248
  7. Howard DN, Chambers C, Cusano F. Efficacy vs. effectiveness – docetaxel and prednisone in hormone refractory prostate cancer. J. Oncol. Pharm. Pract. 2008;14:45–49
  8. Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2008;26:5261–5268
  9. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008;6:1–18
  10. Moriyama-Gonda N, Shiina H, Terashima M, Satoh K, Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU. Int. 2008;101:485–491
  11. Villar J, Quadri HS, Song I, Tomita Y, Tirado OM, Notario V. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res. 2009;69:102–110
  12. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687
  13. Garcia-Alvarez B, de Pereda JM, Calderwood DA, Ulmer TS, Critchley D, Campbell ID, et al. Structural determinants of integrin recognition by talin. Mol. Cell. 2003;11:49–58
  14. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003;301:1720–1725
  15. Lock JG, Wehrle-Haller B, Stromblad S. Cell-matrix adhesion complexes: master control machinery of cell migration. Semin. Cancer Biol. 2008;18:65–76
  16. Larjava H, Plow EF, Wu C. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO. Rep. 2008;9:1203–1208
  17. Montanez E, Ussar S, Schifferer M, Bosl M, Zent R, Moser M, et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008;22:1325–1330
  18. Harburger DS, Bouaouina M, Calderwood DA. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J. Biol. Chem. 2009;284:11485–11497
  19. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J. Cell Biol. 2008;181:439–446
  20. Shi X, Ma YQ, Tu Y, Chen K, Wu S, Fukuda K, et al. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J. Biol. Chem. 2007;282:20455–20466
  21. Dowling JJ, Gibbs E, Russell M, Goldman D, Minarcik J, Golden JA, et al. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ. Res. 2008;102:423–431
  22. Rogalski TM, Mullen GP, Gilbert MM, Williams BD, Moerman DG. The UNC-112 gene in Caenorhabditis elegans encodes a novel component of cell-matrix adhesion structures required for integrin localization in the muscle cell membrane. J. Cell Biol. 2000;150:253–264
  23. Tu Y, Wu S, Shi X, Chen K, Wu C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003;113:37–47
  24. Ussar S, Wang HV, Linder S, Fassler R, Moser M. The kindlins: subcellular localization and expression during murine development. Exp. Cell Res. 2006;312:3142–3151
  25. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science. 2003;302:103–106
  26. Kato K, Shiozawa T, Mitsushita J, Toda A, Horiuchi A, Nikaido T, et al. Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum. Pathol. 2004;35:55–60
  27. Z. An, K. Dobra, J.G. Lock, S. Stromblad, A. Hjerpe, H. Zhang, Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration, Int. J. Cancer 2010 Febuary 2 (Epub ahead of print).
  28. Lai-Cheong JE, Ussar S, Arita K, Hart IR, McGrath JA. Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J. Invest. Dermatol. 2008;128:2156–2165
  29. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008;134:353–364
  30. Herz C, Aumailley M, Schulte C, Schlotzer-Schrehardt U, Bruckner-Tuderman L, Has C. Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. J. Biol. Chem. 2006;281:36082–36090
  31. Weinstein EJ, Bourner M, Head R, Zakeri H, Bauer C, Mazzarella R. URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas. Biochim. Biophys. Acta. 2003;1637:207–216
  32. Shi X, Wu C. A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion. Mol. Cancer Res. 2008;6:715–724
  33. Salido M, Larran J, Lopez A, Vilches J, Aparicio J. Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP. Histol. Histopathol. 1999;14:125–134
  34. Ren A, Yan G, You B, Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 2008;68:2266–2274
  35. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, et al. A phase I–II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 2008;14:6270–6276
  36. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, et al. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer. 2005;4:138–141

PII: S0304-3835(10)00384-8

doi: 10.1016/j.canlet.2010.08.003

Cancer Letters
Volume 299, Issue 1 , Pages 54-62 , 18 December 2010

Article Tools

* Image Usage & Resolution